Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an umbrella term that covers both a relatively benign condition, which is simple steatosis, and nonalcoholic steatohepatitis (NASH). NASH is characterized by a chronic and progressive liver pathology that may progress to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and liver transplantation. Despite the growing body of evidence, one of the important and unresolved problems is the pathogenesis of NASH. It might be a metabolic disturbance as a primary abnormality in NAFLD. Insulin resistance is at the center of these metabolic abnormalities. Then, hepatocyte injury might be induced by oxidative stress. This ongoing process progresses to NASH, even to cirrhosis in some patients. In addition to oxidative stress, possibilities for the next hit are lipid peroxidation, reactive metabolites, adipose tissue products, transforming growth factor-β₁, Fas ligand, mitochondrial dysfunction, respiratory chain deficiency, and intestinal microbiota. Currently, there is no well-established and approved therapy. Recommendations are to improve existing co-morbidities, such as obesity, hyperlipidemia, or type 2 diabetes, and lifestyle modification with weight loss and exercise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“A meta-analysis of studies performed with thiazolidines showed improvements in steatosis, hepatocyte ballooning, and inflammation but not in fibrosis (49-55).”
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 4×
“Adipose tissue is now recognized as a source of important inflammatory mediators and adipokines, such as pro-inflammatory (leptin, TNF- α, and IL-6) and anti-inflammatory (adiponectin) effects (13-16).”
BackgroundInfluentialSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Samuel, B. S., Shaito, A., Motoike, T., Rey, F. E., Backhed, F., Manchester, J. K., Hammer, R. E., Williams, S. C., Crowley, J., Yanagisawa, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808567105 · Cited by 1,564 · cited 1×
“Germ-free (GF) C57BL/6J mice are microbe-free and resistant to diet-induced obesity (31-34).”
BackgroundFatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Erridge, C., Attina, T., Spickett, C. M., & Webb, D. J. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1286 · Cited by 776
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“A meta-analysis of studies performed with thiazolidines showed improvements in steatosis, hepatocyte ballooning, and inflammation but not in fibrosis (49-55).”
Interplay between obesity and associated metabolic disorders: New insights into the gut microbiota
Cani, P. D., & Delzenne, N. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.016 · Cited by 377 · cited 1×
“Proposed mechanisms for the role of gut microbiota include the provision of additional energy by the conversion of dietary fiber to short-chain fatty acids, effects on gut hormone production, increased intestinal permeability causing elevated systemic levels of lipopolysaccharides (LPS), and the innate immune system,…”
BackgroundEffects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Cited by
Oxidative stress in obesity: A critical component in human diseases
Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G., Gitto, E., & Arrigo, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010378 · Cited by 933
“Increased delivery of both FFA and TG to the liver, decreased liver utilization of FFA, diminished export of TG from the liver and impaired β-oxidation of FFA within hepatocytes cause TG accumulation within the cytoplasm of hepatocytes [115,116].”
BackgroundThe effect of probiotics on inflammatory biomarkers: A meta-analysis of randomized clinical trials
Milajerdi, A., Mousavi, S. M., Sadeghi, A., Salari-Moghaddam, A., Parohan, M., Larijani, B., & Esmaillzadeh, A. (2020) · European Journal of Nutrition · doi:10.1007/s00394-019-01931-8 · Cited by 123
Beba, M., Djafarian, K., & Shab-Bidar, S. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.08.002 · Cited by 15
Castelão-Baptista, J. P., Valente, S. A., Canário, S., Oppolzer, D., Barros, A., Venâncio, C., Martins, T., Antunes, L., Sardão, V. A., Rosa, E., et al. (2023) · Nutrients · doi:10.3390/nu15040924 · Cited by 5
“NAFLD involves an excessive accumulation of fatty acids in the liver without significant alcohol consumption [8,9].”
BackgroundInfluential
Metadata
- Authors
- Basaranoglu, M., & Ormeci, N.
- Venue
- The Turkish Journal of Gastroenterology
- Publisher
- AVES YAYINCILIK A.Ş.
- Published
- 2014-07-06
- Volume
- 25
- Issue
- 2
- Pages
- 127-132
- ISSN
- 1300-4948 (ISSN-L)
- OpenAlex
- W2096197155
- Cited by
- 48
- References
- 10
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.